Scandinavian ChemoTech's subsidiary Vetiqure AB has initiated TSE treatments on horses

Vetiqure AB, which primarily concentrates on Tumour Specific Electroporation (TSE) for veterinary medicine, has now, together with its partner Evidensia Helsingborg, initiated TSE treatments on horses.

The treatment was performed on sarcoids, which are a wart-like form of tumour in the skin of horses. These tumours are common but painful and affect many horses.

" We are awaiting more information but are very positive that we are now starting the journey with TSE treatments also in the category of large animals. The market for sarcoids on large animals has great potential in Europe, North America and the Middle East." - says Mohan Frick, CEO Scandinavian ChemoTech AB

For further information please contact: Mohan Frick, CEO

+46 (0)10-218 93 00

info@chemotech.se

Certified Adviser: Erik Penser Bank, Tel: +46 8 463 80 00E-mail: certifiedadviser@penser.se

Scandinavian ChemoTech AB (publ)
ChemoTech is a Swedish medical technology company based in Lund that has developed a patented technology platform to offer cancer patients access to a new treatment alternative, Tumour Specific Electroporation™ (TSE), available for treatment of both humans and animals. There are a large number of cancer patients whose tumours for various reasons cannot be treated by conventional methods but where TSE can be a solution. Therefore, the company continuously evaluates new opportunities and areas of application for the technology. ChemoTech's shares (CMOTEC B) are listed on Nasdaq First North Growth Market in Stockholm and Erik Penser Bank is the company's Certified Adviser. Read more at: www.chemotech.se.

Subscribe

Media

Media